In Brief: Fresenius USA
This article was originally published in The Gray Sheet
Executive SummaryFresenius USA: Dialysis equipment manufacturer plans first quarter 1998 North American roll-out of its On-Line Clearance (OLC) dialysis dose monitor for end stage renal disease patients, the company says. The device, which gained 510(k) clearance in June, can be retrofitted to the Fresenius 2008H dialysis machine and will be included on 70-80% of all new machines sold, the firm says. Unlike competing devices, the OLC immediately provides nephrologists with treatment dose information, Fresenius maintains...
You may also be interested in...
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.